chronic kidney disease with type 2 diabetes
Endocrinology · 2022–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| finerenone Treatment of chronic kidney disease associated with type 2 diabetes mellitus with albuminuria, to delay progressive decline of kidney function and reduce the… | Jul 2022 | Not recommended | input received Diabetes Australia |
Who spoke
Diabetes Australia
What the PBS pays
$4M in government benefit over 2024–25, across 55,868 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| finerenone | $4.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| finerenoneFinerenone for treating chronic kidney disease in type 2 diabetes | TA877 | recommended restricted | 2023-03 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.